Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second
Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.
How this was made

The 30-second read
Why it matters
The earnings call provides fresh guidance and margin details that could move PHAT and affect biotech sentiment.
Market read
Earnings and guidance could drive PHAT's stock and influence the broader biotech sector.
What to watch
Potential upside from upcoming Phase 2 data and business development opportunities.
Background
Phathom Pharmaceuticals held its Q3 2026 earnings call, discussing results and outlook.
Ticker impact
Q3 earnings reveal a one-time manufacturing charge causing margin decline and Q4 guidance set at the lower end of the 55%-59% range.
likely modest pressure as market prices in the margin decline and guidance uncertainty
One-time charge hurts gross margin, while guidance remains conservative, suggesting limited upside potential.
Market effects
Biotech earnings may influence sentiment across small-cap pharma stocks.
Primarily impacts U.S. biotech investors.
Limited to niche biotech sector, no broad market effect.
Counterpoint
Margin decline could be temporary; guidance may be upgraded if pipeline progresses.
Key entities
- companyPhathom Pharmaceuticals Inc.
Biopharmaceutical company reporting Q3 results.
- personSteve Basta
CEO of Phathom Pharmaceuticals.
- personSanjeev Narula
CFO of Phathom Pharmaceuticals.


